Comparative Pharmacology
Head-to-head clinical analysis: CHOLESTYRAMINE LIGHT versus COLESTID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLESTYRAMINE LIGHT versus COLESTID.
CHOLESTYRAMINE LIGHT vs COLESTID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby preventing enterohepatic recirculation of bile acids and promoting hepatic conversion of cholesterol to bile acids, reducing serum LDL-cholesterol.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in the feces, thereby increasing fecal loss of bile acids and reducing enterohepatic circulation of bile salts. This leads to increased hepatic conversion of cholesterol to bile acids, reduction in hepatic cholesterol stores, and decreased plasma LDL cholesterol levels.
4 g orally once or twice daily, increased gradually to 4 g 1-6 times daily; maintenance 4-24 g/day in divided doses.
5-10 g orally once or twice daily, maximum 30 g/day.
None Documented
None Documented
Not applicable; cholestyramine is not absorbed systemically and has no plasma half-life; clinical effect duration reflects gastrointestinal transit time.
Not applicable due to non-systemic action; local gastrointestinal half-life not clinically defined
Primarily fecal as bile acid complex; <0.05% renal excretion of unchanged drug; negligible systemic absorption.
Primarily fecal (≥95%) as unchanged drug; minimal renal excretion (<5%)
Category C
Category C
Bile Acid Sequestrant
Bile Acid Sequestrant